Amelioration of experimental autoimmune encephalitis by novel peptides: Involvement of T regulatory cells

Journal of Autoimmunity

Volumn 35, Issue 1, 2010, Pages 98-106

  Shapira, Elena ^a   Brodsky, Berta ^a   Proscura, Elena ^a   Nyska, Abraham ^b   Erlanger Rosengarten, Avigail ^a   Wormser, Uri ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 23; JAPANESE RICE EXTRACT; LYSYLGLYCYLHISTIDYLTYROSYLALANYLGLUTAMYLARGINYLVALYLGLYCINE; NONAPEPTIDE; PLANT EXTRACT; PROTEIN RA1; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; CD4 ANTIGEN; CYTOKINE; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, MOUSE; FREUND ADJUVANT; GLYCOPROTEIN; HISTONE; INTERLEUKIN 2 RECEPTOR ALPHA; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN (35-55); MYELIN PROTEOLIPID PROTEIN (139-151); PEPTIDE FRAGMENT; PROTEOLIPID PROTEIN; VEGETABLE PROTEIN;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; AUTOIMMUNITY; BRAIN LEVEL; CD4+ CD25+ T LYMPHOCYTE; CELL ISOLATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; IMMUNOMODULATION; IN VITRO STUDY; JAPAN; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RAT; REGULATORY T LYMPHOCYTE; SPLEEN CELL; ANIMAL; BIOSYNTHESIS; BRAIN; C57BL MOUSE; CELL CULTURE; CELL PROLIFERATION; CHEMISTRY; DISEASE COURSE; DISEASE MODEL; DRUG EFFECTS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; IMMUNOLOGY; LEWIS RAT; METABOLISM; PATHOLOGY; RICE; SECRETION (PROCESS);

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIGENS, CD4; BRAIN; CELL PROLIFERATION; CELLS, CULTURED; CYTOKINES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; FREUND'S ADJUVANT; GLYCOPROTEINS; HISTONES; HUMANS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MICE; MICE, INBRED C57BL; MULTIPLE SCLEROSIS; MYELIN PROTEOLIPID PROTEIN; ORYZA SATIVA; PEPTIDE FRAGMENTS; PLANT EXTRACTS; PLANT PROTEINS; RATS; RATS, INBRED LEW; T-LYMPHOCYTES, REGULATORY; MYELIN-OLIGODENDROCYTE GLYCOPROTEIN;

EID: 77953290714     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2010.03.004     Document Type: Article

References (46)

1. Dhib-Jalbut S. Pathogenesis of myelin/oligodendrocyte damage in multiple sclerosis. Neurology 2007, 68:S13-S21.
2. Lisak R.P., Hohlfeld R. Neurodegeneration, neuroprotection, glial cells, and myelin in multiple sclerosis. Neurology 2007, 68:S1.
3. Lassmann H. Multiple sclerosis: is there neurodegeneration independent from inflammation?. J Neurol Sci 2007, 259:3-6.
4. McFarland H.F., Martin R. Multiple sclerosis: a complicated picture of autoimmunity. Nat Immunol 2007, 8:913-919.
5. Ghezzi A., Amato M.P., Annovazzi P., Capobianco M., Gallo P., La Mantia L., et al. Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience. Neurol Sci 2009, 30:193-199.
6. Hutchinson M., Kappos L., Calabresi P.A., Confavreux C., Giovannoni G., Galetta S.L., et al. Erratum: the efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. J Neurol 2009, 256:1035-1037.
7. Havrdova E., Galetta S., Hutchinson M., Stefoski D., Bates D., Polman C.H., et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol 2009, 8:254-260.
8. Schwartzman R.J., Simpkins N., Alexander G.M., Reichenberger E., Ward K., Lindenberg N., et al. High-dose cyclophosphamide in the treatment of multiple sclerosis. CNS Neurosci Ther 2009, 15:118-127.
9. Moharregh-Khiabani D., Linker R.A., Gold R., Stangel M. Fumaric acid and its esters: an emerging treatment for multiple sclerosis. Curr Neuropharmacol 2009, 7:60-64.
10. Markowitz C.E., Spitsin S., Zimmerman V., Jacobs D., Udupa J.K., Hooper D.C., et al. The treatment of multiple sclerosis with inosine. J Altern Complement Med 2009, 15:619-625.
11. Weiner H.L. Oral laquinimod for treatment of relapsing-remitting multiple sclerosis. Lancet Neurol 2008, 7:672-673.
12. Brodsky B., Erlanger-Rosengarten A., Proscura E., Shapira E., Wormser U. From topical antidote against skin irritants to a novel counter-irritating and anti-inflammatory peptide. Toxicol Appl Pharmacol 2008, 229:342-350.
13. Frohman E.M., Shah A., Eggenberger E., Metz L., Zivadinov R., Stuve O. Corticosteroids for multiple sclerosis: I. Application for treating exacerbations. Neurotherapeutics 2007, 4:618-626.
14. Tsutsui S., Vergote D., Shariat N., Warren K., Ferguson S.S.G., Power C. Glucocorticoids regulate innate immunity in a model of multiple sclerosis: reciprocal interactions between the A1 adenosine receptor and {beta}-arrestin-1 in monocytoid cells. FASEB J 2008, 22:786-796.
15. Weiner H.L. Multiple sclerosis is an inflammatory T-cell-mediated autoimmune disease. Arch Neurol 2004, 61:1613-1615.
16. + regulatory T cell: a jack of all trades, master of regulation. Nat Immunol 2008, 9:239-244.
17. + regulatory T cells in patients with multiple sclerosis. J Exp Med 2004, 199:971-979.
18. Huan J., Culbertson N., Spencer L., Bartholomew R., Burrows G.G., Chou Y.K., et al. Decreased FOXP3 levels in multiple sclerosis patients. J Neurosci Res 2005, 81:45-52.
19. Penton-Rol G., Cervantes-Llanos M., Cabrera-Gomez J.A., Alonso-Ramirez R., Valenzuela-Silva C., Rodriguez-Lara R., et al. Treatment with type I interferons induces a regulatory T cell subset in peripheral blood mononuclear cells from multiple sclerosis patients. Int Immunopharmacol 2008, 8:881-886.
20. + regulatory T cells by copolymer-I through activation of transcription factor Foxp3. PNAS 2005, 102:6449-6454.
21. Rosati G. The prevalence of multiple sclerosis in the world: an update. Neurol Sci 2001, 22:117-139.
22. Osoegawa M., Kira J., Fukazawa T., Fujihara K., Kikuchi S., Matsui M., et al. Temporal changes and geographical differences in multiple sclerosis phenotypes in Japanese: nationwide survey results over 30 years. Mult Scler 2009, 15:159-173.
23. Cheng Q., Miao L., Zhang J., Ding S.-J., Liu Z.-G., Wang X., et al. A population-based survey of multiple sclerosis in Shanghai. China Neurol 2007, 68:1495-1500.
24. Carlyle I.P. Multiple sclerosis: a geographical hypothesis. Med Hypotheses 1997, 49:477-486.
25. Resch J. Geographic distribution of multiple sclerosis and its relation to geophysical values. Soz - Praventivmed 1995, 40:161-171.
26. Lensky P. Geographic aspects in the epidemiology of multiple sclerosis. Epidemiol Mikrobiol Imunol 1994, 43:174-176.
27. Liu Y.J., Samuel D., Lin C.H., Lyu P.C. Purification and characterization of a novel 7-kDa non-specific lipid transfer protein-2 from rice (Oryza sativa). Biochem Biophys Res Commun 2002, 294:535-540.
28. Gazal S., Gelerman G., Ziv O., Karpov O., Litman P., Bracha M., et al. Human somatostatin receptor specificity of backbone-cyclic analogues containing novel sulfur building units. J Med Chem 2002, 45:1665-1671.
29. Mizuma T., Masubuchi S., Awazu S. Intestinal absorption of stable cyclic dipeptides by the oligopeptide transporter in rat. J Pharm Pharmacol 1998, 50:167-172.
30. Petereit H.F., Richter N., Pukrop R., Bamborschke S. Interferon gamma production in blood lymphocytes correlates with disability score in multiple sclerosis patients. Mult Scler 2000, 6:19-23.
31. Bettelli E., Korn T., Oukka M., Kuchroo V.K. Induction and effector functions of TH17 cells. Nature 2008, 453:1051-1057.
32. Agostini C., Calabrese F., Rea F., Facco M., Tosoni A., Loy M., et al. CXCR3 and its ligand CXCL10 are expressed by inflammatory cells infiltrating lung allografts and mediate chemotaxis of T cells at sites of rejection. Am J Pathol 2001, 158:1703-1711.
33. Baniyash M. TCR zeta-chain downregulation: curtailing an excessive inflammatory immune response. Nat Rev Immunol 2004, 4:675-687.
34. Beissert S., Schwarz A., Schwarz T. Regulatory T cells. J Invest Dermatol 2006, 126:15-24.
35. + T regulatory cell-mediated suppression. Immunity 2009, 30:636-645.
36. + Immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2_production. J Exp Med 1998, 188:287-296.
37. + naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int Immunol 1998, 10:1969-1980.
38. + regulatory T cells: independence of IL-2 consumption, TGF-beta, and various inhibitors of TCR signaling. J Immunol 2007, 179:3578-3587.
39. + T cells. Nat Immunol 2007, 8:1353-1362.
40. Collison L.W., Workman C.J., Kuo T.T., Boyd K., Wang Y., Vignali K.M., et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 2007, 450:566-569.
41. + T cells. Blood 2007, 109:2058-2065.
42. Grossman W.J., Verbsky J.W., Barchet W., Colonna M., Atkinson J.P., Ley T.J. Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity 2004, 21:589-601.
43. + regulatory cells involves a granzyme B-dependent, perforin-independent mechanism. J Immunol 2005, 174:1783-1786.
44. Matsushita T., Yanaba K., Bouaziz J.D., Fujimoto M., Tedder T.F. Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J Clin Invest 2008, 118:3420-3430.
45. Yanaba K. Regulatory B cells. Jpn J Clin Immunol 2009, 32:135-141.
46. Bouaziz J.D., Yanaba K., Tedder T.F. Regulatory B cells as inhibitors of immune responses and inflammation. Immunol Rev 2008, 224:201-214.